Cingulate therapeutics headquarters
WebJun 15, 2024 · KANSAS CITY, Kan., June 15, 2024 /PRNewswire/ -- Cingulate Therapeutics, LLC, a privately held clinical stage biopharmaceutical company focused on... WebJun 15, 2024 · Kansas City, KS – (June 15, 2024) – Cingulate Therapeutics, LLC, a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), today announced that it has moved the location of its Kansas City headquarters.
Cingulate therapeutics headquarters
Did you know?
WebView Arthur Straughn's business profile as Co-founder Board of Directors at Cingulate Therapeutics. Find Arthur's email address, mobile number, work history, and more. Product About Create Free Account. Wrong ... Arthur Straughn's HQ phone number is +1 913-942-2300. Who are Arthur Straughn's colleagues? Arthur Straughn's colleagues are Lou Horn ... WebCingulate Therapeutics has raised a total of $7.6M in funding over 3 rounds. Their latest funding was raised on Jul 11, 2024 from a Venture - Series Unknown round. Cingulate Therapeutics is registered under the ticker NASDAQ:CING . Their stock opened with $6.00 in its Dec 8, 2024 IPO.
WebJul 11, 2024 · Jul 11, 2024. Updated Jul 11, 2024, 2:54pm CDT. Cingulate Therapeutics LLC, a Kansas City, Kan., pharmaceutical startup, received a big equity investment and … WebJun 24, 2024 · Virtual. We are pleased to invite you to a virtual call series highlighting the next generation of life sciences private companies from Monday, June 29 th – Thursday, July 2 nd, 2024. We will be hosting the companies for 35 minute presentations with time for Q&A over the four days.
WebCingulate Therapeutics is headquartered in Mission, 1901 W 47th Pl, United States, and has 2 office locations. WebJun 15, 2024 · Cingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products …
WebJun 16, 2024 · Cingulate Therapeutics, a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment …
WebCingulate Therapeutics is a biopharmaceutical company developing products for the treatment of central nervous system and neurobiological disorders. greens home for women fayetteville ncWebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. … 10 Mar 2024 Cingulate Inc. Reports Fourth Quarter and Full Year 2024 Financial … Pipeline Overview. Cingulate® completed a proof-of-concept trial in human subjects … Cingulate Inc. 1901 W 47th Place Kansas City, KS 66205 (913) 942-2300 … Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and … About Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage … Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member … fmsandhyanee fontWebCingulate Therapeutics Primary Sponsor contact: Holly Mitzel Cingulate Therapeutics 1901 W. 47th Place, Suite 310 Kansas City, KS 66205 E: [email protected] P: 913-942-2304 Secondary Sponsor contact: Matt Brams, MD Cingulate Therapeutics 1901 W. 47th Place, Suite 310 Kansas City, KS … greenshoot capital charlestonWebMar 10, 2024 · KANSAS CITY, Kan., March 10, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug... fms aod codesWebDec 8, 2024 · KANSAS CITY, Kan., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing... greens hollymead charlottesvilleWebCingulate is headquartered in Kansas City. For more information visit Cingulate.com. Forward-Looking Statements This press release contains certain forward-looking statements, including those relating to the use of proceeds and other statements that are predictive in nature. fms argentina wiki rapWebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ … fms apple